(41, 42) have demonstrated that SLFN12 exerts a potentiation effect on the responsiveness of triple-negative breast cancer (TNBC) to DNA-damaging therapies, which is achieved in part through the suppression of CHK1/2 phosphorylation. This evidence concerns the gene SLFN12 and triple-negative breast carcinoma.